Swiss dermatology company Galderma is to invest more than $650 million (£520 million) in US manufacturing by 2030 as it expands its presence in the country, its fastest-growing market.
The investment will support production of brands including Cetaphil and Alastin, as well as the final assembly and packaging of Nemluvio, a treatment for prurigo nodularis and moderate-to-severe atopic dermatitis.
Galderma said the programme includes a dedicated production line in Florida, backed by an investment of about $150 million, while more than $500 million will be spent over the next five years on US production of the full Alastin range and selected Cetaphil products.
The company will use contract manufacturing partners for the work and has begun technology transfers aimed at increasing domestic capacity. The plans also include developing US production capacity for Relfydess, its next-generation injectable treatment.
Galderma’s US manufacturing investment
Flemming Ørnskov, Galderma’s chief executive, said the scale of the American market made investment there essential. “If you want to succeed, you have to succeed in the U.S.,” he said.
Galderma generated record net sales of $5.207 billion in 2025, according to its annual results. US sales rose 23.3 per cent to $2.231 billion, accounting for more than two-fifths of the group’s revenue.
The company’s portfolio spans skincare, therapeutic dermatology and injectable aesthetics. Its brands include Cetaphil, Alastin, Sculptra and Restylane, while its main US competitor in injectables is Allergan Aesthetics, owned by AbbVie and best known for Botox and Juvéderm.
Ørnskov said Galderma would not consider its expansion complete until it had narrowed the market-share gap with Allergan. The company is also seeking access to specialist research and commercial talent across several US locations.
Galderma moved its US and Latin American headquarters to Miami in June 2025, while establishing a global research and development hub in Boston. It has also expanded its presence in Carlsbad, California, which serves as a centre for Alastin, and retained Fort Worth, Texas, as a major North American distribution hub.
Ørnskov said Boston was chosen to improve access to research talent and compete with large pharmaceutical companies such as Sanofi, whose Dupixent treatment competes with Galderma’s Nemluvio in some skin conditions.
He added that the US regulatory process for aesthetic products was the toughest in the world, but said the importance of the market meant the company had to continue investing despite the hurdles.
